Analysts See $0.06 EPS for JA Solar Holdings Co., Ltd. (JASO); Shorts at Pain Therapeutics (PTIE) Lowered By 4.05%

February 18, 2018 - By Linda Rogers

Pain Therapeutics Incorporated (NASDAQ:PTIE) had a decrease of 4.05% in short interest. PTIE’s SI was 1.10 million shares in February as released by FINRA. Its down 4.05% from 1.15M shares previously. With 49,600 avg volume, 22 days are for Pain Therapeutics Incorporated (NASDAQ:PTIE)’s short sellers to cover PTIE’s short positions. The stock decreased 1.10% or $0.07 during the last trading session, reaching $6.28. About 29,763 shares traded. Pain Therapeutics, Inc. (NASDAQ:PTIE) has declined 72.83% since February 18, 2017 and is downtrending. It has underperformed by 89.53% the S&P500.

Analysts expect JA Solar Holdings Co., Ltd. (NASDAQ:JASO) to report $0.06 EPS on March, 15.They anticipate $0.92 EPS change or 93.88% from last quarter’s $0.98 EPS. JASO’s profit would be $2.81 million giving it 30.67 P/E if the $0.06 EPS is correct. After having $0.13 EPS previously, JA Solar Holdings Co., Ltd.’s analysts see -53.85% EPS growth. The stock decreased 0.67% or $0.05 during the last trading session, reaching $7.36. About 366,037 shares traded. JA Solar Holdings Co., Ltd. (NASDAQ:JASO) has declined 7.04% since February 18, 2017 and is downtrending. It has underperformed by 23.74% the S&P500.

Among 5 analysts covering JA Solar (NASDAQ:JASO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. JA Solar had 13 analyst reports since August 12, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Outperform” rating and $10 target in Wednesday, August 12 report. The firm earned “Buy” rating on Thursday, October 6 by Axiom Capital. On Wednesday, December 16 the stock rating was upgraded by TH Capital to “Buy”. Roth Capital maintained the stock with “Hold” rating in Wednesday, August 23 report. The firm earned “Sell” rating on Monday, August 31 by Axiom Capital. The rating was downgraded by Axiom Capital to “Sell” on Tuesday, August 29. Roth Capital downgraded it to “Neutral” rating and $8 target in Friday, June 3 report. The firm earned “Hold” rating on Wednesday, July 19 by Axiom Capital. As per Wednesday, November 16, the company rating was downgraded by Axiom Capital. The rating was maintained by Roth Capital with “Neutral” on Saturday, August 15.

JA Solar Holdings Co., Ltd., together with its subsidiaries, designs, develops, makes, and sells solar power products based on crystalline silicon technologies. The company has market cap of $344.98 million. The company's principal products include monocrystalline and multicrystalline solar cells and modules. It has a 4.3 P/E ratio. It also provides monocrystalline and multicrystalline silicon wafers; solar product processing services; and solar power plant project development and electricity generation services.

Pain Therapeutics, Inc., a biopharmaceutical company, develops drugs for treating nervous system in the United States. The company has market cap of $41.42 million. The companyÂ’s lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. It currently has negative earnings. It also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat AlzheimerÂ’s disease and other neurological disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Linda Rogers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: